Providing Access to Unlicensed Medicines
The Role of Pharmaceutical Manufacturers
What’s driving demand for unlicensed medicines in non-launch or non-com-mercialised markets? And what are the challenges for the pharmaceutical manufacturer of not actively engaging in providing access?
Irrespective of the manufacturers stance, demand will still exist in unlicensed markets. Healthcare professionals and patients will look to source the drug elsewhere. Without a corporate solution in place, allowing controlled access, what are the risks being taken by the manufacturer?